SCA
EBS icon

SAC Capital Advisors’s Emergent Biosolutions EBS Stock Holding History

SAC Capital Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-401,847
Closed -$10.2M – 314
2014
Q1 		$10.2M Sell
401,847
-511,969
-56% -$12.9M 0.05% 398
2013
Q4 		$21M Buy
913,816
+60,068
+7% +$1.25M 0.12% 200
2013
Q3 		$16.3M Buy
853,748
+323,083
+61% +$5.77M 0.09% 273
2013
Q2 		$7.65M Buy
+530,665
New +$7.68M 0.04% 429

Other funds holding EBS

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAC Capital Advisors's EBS Position: Q2 2014 in Review

SAC Capital Advisors sold out of Emergent Biosolutions (EBS) in Q2 2014, closing a stake of 401,847 shares — an estimated $10.2M sold.

SAC Capital Advisors first reported a position in EBS in Q2 2013 and held it in 4 quarters. The position peaked at $21M in Q4 2013. 160 funds tracked by Wall St. Rank hold EBS as of Q2 2014.

  • SAC Capital Advisors reported no remaining Emergent Biosolutions position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 401,847 Emergent Biosolutions shares in Q2 2014, an estimated $10.2M.
  • SAC Capital Advisors first reported a position in Emergent Biosolutions in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Emergent Biosolutions position peaked at $21M in Q4 2013.
  • 160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.